Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2009 1
2011 2
2012 1
2014 1
2015 5
2016 4
2017 7
2018 8
2019 2
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all
Page 1
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Al-Batran SE, et al. Among authors: haag gm. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. Lancet. 2019. PMID: 30982686 Clinical Trial.
Hematological Malignancies in Adults With a Family Predisposition.
Bochtler T, Haag GM, Schott S, Kloor M, Krämer A, Müller-Tidow C. Bochtler T, et al. Among authors: haag gm. Dtsch Arztebl Int. 2018 Dec 14;115(50):848-854. doi: 10.3238/arztebl.2018.0848. Dtsch Arztebl Int. 2018. PMID: 30722840 Free PMC article. Review.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Al-Batran SE, et al. Among authors: haag gm. Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22. Lancet Oncol. 2016. PMID: 27776843 Clinical Trial.
Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM, Czink E, Ahadova A, Schmidt T, Sisic L, Blank S, Heger U, Apostolidis L, Berger AK, Springfeld C, Lasitschka F, Jäger D, von Knebel Doeberitz M, Kloor M. Haag GM, et al. Int J Cancer. 2019 Apr 1;144(7):1697-1703. doi: 10.1002/ijc.32030. Epub 2019 Jan 4. Int J Cancer. 2019. PMID: 30499151 Free article.
Immunotherapy of Colorectal Cancer.
Jäger D, Halama N, Zörnig I, Klug P, Krauss J, Haag GM. Jäger D, et al. Among authors: haag gm. Oncol Res Treat. 2016;39(6):346-50. doi: 10.1159/000446713. Epub 2016 May 25. Oncol Res Treat. 2016. PMID: 27259331 Review.
Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
Heger U, Sisic L, Nienhüser H, Blank S, Hinz U, Haag GM, Ott K, Ulrich A, Büchler MW, Schmidt T. Heger U, et al. Among authors: haag gm. Ann Surg Oncol. 2018 Aug;25(8):2418-2427. doi: 10.1245/s10434-018-6541-3. Epub 2018 May 31. Ann Surg Oncol. 2018. PMID: 29855828
Prognostic differences in 8th edition TNM staging of esophagogastric adenocarcinoma after neoadjuvant treatment.
Sisic L, Blank S, Nienhüser H, Dorr S, Haag GM, Jäger D, Bruckner T, Müller-Stich BP, Ott K, Büchler MW, Ulrich A, Schmidt T. Sisic L, et al. Among authors: haag gm. Eur J Surg Oncol. 2018 Oct;44(10):1646-1656. doi: 10.1016/j.ejso.2018.06.030. Epub 2018 Jul 7. Eur J Surg Oncol. 2018. PMID: 30082176
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, Funk J, Ziegelmeier C, Juenger S, Bucur M, Umansky L, Falk CS, Freitag A, Karapanagiotou-Schenkel I, Beckhove P, Enk A, Jaeger D. Haag GM, et al. Eur J Cancer. 2018 Feb;90:122-129. doi: 10.1016/j.ejca.2017.12.001. Epub 2018 Jan 5. Eur J Cancer. 2018. PMID: 29306769 Clinical Trial.
Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease.
Zschäbitz S, Distler FA, Krieger B, Wuchter P, Schäfer-Eckart K, Jenzer M, Hohenfellner M, Dreger P, Haag GM, Jäger D, Pahernik S, Grüllich C. Zschäbitz S, et al. Among authors: haag gm. Oncotarget. 2018 Apr 27;9(32):22537-22545. doi: 10.18632/oncotarget.25162. eCollection 2018 Apr 27. Oncotarget. 2018. PMID: 29854297 Free PMC article.
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
Berger AK, Lücke S, Abel U, Haag GM, Grüllich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, Lordick F, Haberkorn U, Jäger D. Berger AK, et al. Among authors: haag gm. Br J Cancer. 2018 Jul;119(2):170-175. doi: 10.1038/s41416-018-0152-4. Epub 2018 Jul 2. Br J Cancer. 2018. PMID: 29961759 Free PMC article. Clinical Trial.
33 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback